BiotechTube

NVX-CoV2373 + BBIBP-CorV vaccine

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Trial Timeline

Mar 18, 2022 → May 4, 2023

NCT ID
NCT05249816

About NVX-CoV2373 + BBIBP-CorV vaccine

NVX-CoV2373 + BBIBP-CorV vaccine is a phase 3 stage product being developed by Novavax for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The current trial status is completed. This product is registered under clinical trial identifier NCT05249816. Target conditions include Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05249816Phase 3Completed

Competing Products

20 competing products in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
80
Drotrecogin alfa (activated)Eli LillyPhase 2
52
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
CS-3150Daiichi SankyoPhase 3
77
tacrolimusAstellas PharmaApproved
85
enzalutamideAstellas PharmaPhase 1
33
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
77
AlefaceptAstellas PharmaApproved
85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
65
CefiderocolShionogiApproved
85
eritoran tetrasodium + PlaceboEisaiPhase 3
77
Donepezil HClEisaiApproved
85
Donepezil Hydrochloride (Aricept)EisaiApproved
85
KHK4827 + PlaceboKyowa KirinPhase 3
77

Other Products from Novavax

Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)Approved
80
protein subunit: Novavax COVID-19 vaccine + Pfizer mRNA COVID-19 vaccineApproved
80
NVX-CoV2705 + PlaceboApproved
80
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)Phase 3
72
RSV-F Vaccine + Phosphate Buffer PlaceboPhase 3
72